Clinical Trial Update: Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation [Phase 2]

View source ↗

Summary

A Phase 2 trial updating on the combination of surufatinib and tislelizumab for advanced non-small cell lung cancer with neuroendocrine differentiation; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Surufatinib (Surufatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: National Cancer Center, China | Conditions: NSCLC | Phase 2 | Status: NOT_YET_RECRUITING